Project Grant R21AI202820
- The National Institute of Allergy and Infectious Diseases awarded Emory University $3,094,830 under Project Grant R01AI201564 on September 1, 2026, to investigate reassortment of highly pathogenic avian influenza viruses and its effects on viral fitness and host range adaptation. The award funds research examining how H5N1 clade 2.3.4.4B viruses exchange genetic segments with low-pathogenicity avian influenza viruses and human-adapted influenza viruses, with particular focus on assessing...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $772,008 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify spike protein correlates driving merbecovirus pathogenesis. The funded research examines how motifs in the S1/S2 loop of MERS-CoV and merbecovirus spike proteins affect infection and pathogenesis by modulating spike cleavage efficiency, spike processing on virions, and cellular entry routes (endosomal...
- Federal Grant Award Summary Emory University received a $160,546.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 3, 2025, through August 31, 2029. The project, titled "Towards Foundation Epidemic Models for Respiratory Infections: A Novel Spatiotemporal Machine Learning Framework," will be conducted at Emory's Atlanta, Georgia campus. This award...
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $795,962 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how gut microbiota composition influences respiratory viral infection outcomes and alveolar macrophage function. The research examines the protective mechanisms by which segmented filamentous bacteria (SFB) colonization in the intestine confers resistance to severe...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $412,749 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into enhancers that facilitate genetic manipulation of specific B-cell subsets. The research identifies cis-regulatory elements (enhancers) that control cell-type and context-specific gene expression in memory B cells and antibody-secreting plasma cells, with the goal of developing precise genetic...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $922,840 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate inducible hepatic-associated lymphoid tissue and the generation and maintenance of long-lived plasma cells during hepatotropic viral infection. The funded research uses rodent hepacivirus, a newly discovered animal model of infection that replicates key features of hepatitis C virus, to examine how...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $2.959 million on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support the Michigan Influenza Transmission Research Center's observational studies of human influenza transmission. The award funds three coordinated research projects examining influenza transmission through the epidemiologic triangle framework of pathogen, host, and...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded the University of Missouri System $805,253 on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms underlying airborne transmission of seasonal influenza A viruses, specifically H1N1 and H3N2 subtypes. The recipient will characterize aerosol particle size distributions and virion morphologies of H1N1 and H3N2 using samples from human patients, laboratory-generated...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded $149,190 to the University of Massachusetts Medical School on December 17, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a project grant (F31AI191745) to investigate hemagglutinin-mediated molecular mechanisms of avian influenza A virus host tropism. The research examines how the hemagglutinin (HA)...
The National Institute of Allergy and Infectious Diseases awarded Emory University $233,118 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the mechanistic rules governing respiratory virus transmission through integrated analysis of ferret contact patterns and viral dynamics. The project addresses gaps in understanding influenza A virus transmission routes—contact, droplet, airborne, and fomite—by combining video datasets from controlled ferret transmission experiments, daily viral load measurements, and high-resolution behavioral tracking using SLEAP (Social Leap Estimates Animal Poses), an open-source deep learning system. Aim 1 extracts time-resolved behavioral data from recorded ferret experiments to generate quantitative exposure histories for each recipient ferret, including contact duration, distance relative to infected donors, and object-sharing interaction sequences. These data will classify behavioral patterns, identify features most predictive of infection outcomes, and construct exposure matrices linking donor and recipient ferrets. Aim 2 integrates behavioral metrics with within-host viral dynamic models to infer mechanistic transmission kernels—mathematical functions describing how infection probability scales with viral load, contact duration, proximity, and fomite-mediated exposure. Bayesian hierarchical methods will account for experimental heterogeneity and estimate biologically interpretable parameters such as per-minute transmission hazard and fomite decay rate. Performance occurs at Atlanta, Georgia. The period of performance runs through July 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $233.1k | 8/17/26 |